Sponsored Content | Case Study | Radiation Oncology | September 04, 2019

First Clinical Experience With the RayCare OIS

Iridium Cancer Network

Iridium Cancer Network

Piet Dirix

Piet Dirix

Iridium Cancer Network consists of all seven hospitals in the Antwerp region, closely collaborating regarding radiation oncology. The network acts as a single radiation therapy department, making it the largest in Belgium with its annual 5,300 patients. Iridium was first to use the RayCare* oncology information system (OIS) clinically, only two months after it was released from RaySearch.

Iridium Cancer Network became a RaySearch customer in 2015 when choosing RayStation for its treatment planning. Iridium quickly appeared as an obvious choice of clinical partner to develop RayCare, the next-generation OIS, as the department spreads over seven hospitals. This, combined with a strong interest for clinical innovation, made the network a very attractive partner to develop aspects of RayCare related to coordinating cancer care efforts between institutions.

It made perfect sense to help RaySearch develop such an OIS, said Piet Dirix, radiation oncologist at Iridium.

“For me, the partnership with RaySearch was an absolute no-brainer. We needed to have an OIS that we could trust and that would help us tremendously with our workflow. Hearing that RaySearch was developing such an OIS and that they were actually looking for clinical partners to develop it with them, I became incredibly enthusiastic and we really wanted to participate in that,” he said.

Seamless Integration With RayStation

Iridium became a clinical partner to RaySearch in late 2015 and has since made a strong contribution to develop RayCare, especially with features that will support coordinated activities between different institutions. The first steps of the clinical use were done with a focus on planning workflow support and image management using RayPACS, a picture archiving and communication system (PACS) that makes it fast and easy to retrieve and share images.

“With RayCare, we can just label an image in RayPACS and then the system handles the import from RayPACS to RayStation. When launching RayStation, the patient information is there, your CT is there and you can start work directly with your patient. This is a big improvement,” Gert De Kerf, medical physics expert, said.

The tight integration between RayCare and RayStation simplifies the teamwork between clinicians, especially when different clinicians can be working on a single patient at different steps of the treatment process.

“Here at Iridium we work as a team to treat the patients. So, it is possible that I delineate a CT scan, that my colleague approves a plan, and another revises the adjustments that are made to the plan. In that way, RayCare is very crucial to the way we work,” said Carole Mercier, radiation oncologist.

“Before the implementation of RayCare we had some problems with commenting when a plan was rejected. Now, thanks to RayCare and the feedback loops, this is simplified,” De Kerf said.

The seamless integration between the systems is great, said Dirix.

“What I am most satisfied with is the close interaction with RayStation. When I push on a certain task in RayCare, RayStation immediately opens at the right patient, in the right time of his or her workflow. This really saves time,” he said.

After a few months of using the RayCare OIS they can already note some efficiency improvements. RayCare and RayStation are used together on one Linac at Iridium, which is actually the linac with the shortest waiting time within the network, according to Dirix.

“There are now around three days wait at the machine where we have RayCare and RayStation, compared to around 21 days at the other linacs. This shows you how powerful the combination is,”
Piet said.

Simplified Workflow

On top of the close interaction with RayStation, RayCare provides other valuable advantages. It has simplified the patient intake consultation process and reduced issues from 25 to 5 percent. RayCare’s schedule automation feature made it much simpler to find the optimal treatment date, eliminating the delays that could result from the complexity of the manual scheduling.

RayCare has been developed by RaySearch to meet the ends of the needs of diverse cancer centers to enable them to give the best possible care to their patients. Therefore, in RayCare digital workflows tailored to the clinic’s needs can be created. The workflows are designed to be highly configurable and tasks for specific staff members can be created automatically, triggered by defined events.

The workflows used at Iridium are custom made and set up in collaboration between Iridium and RaySearch. Six workflows for five tumor groups were specified to Iridium’s needs, with a focus on automation and optimization.

“On the stereotactic treatments we treat five different tumor groups and for these patients six workflows were created. They were all made to our specific needs; for example, we needed an anchor date for an MRI. RayCare now has an anchor date for the MRI,” said Mercier.

Comprehensive Cancer Care is the Future

Centers today often use multiple software systems, including systems for radiation oncology, medical oncology and surgical oncology. The aim with RayCare is to combine these into a single, harmonized system to manage the patient’s entire oncology treatment — from scheduling through treatment delivery and follow-up.

Iridium shares that same ultimate vision of a borderless oncology environment and the future results of the partnerships look very promising.

“I think the future of cancer care will be comprehensive. I think we have to break down the walls between radiation oncology, medical oncology, surgery and especially pathology. These need to be incorporated into a single OIS, and that is exactly what RayCare allows you to do,” said Dirix.

* Subject to regulatory clearance in some markets.

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...